Overcoming resistance to tyrosine kinase inhibitors in renal cell carcinoma

Cancer Treatment Reviews

Volumn 38, Issue 8, 2012, Pages 996-1003

  Ravaud, Alain ^a,b,c   Gross Goupil, Marine ^a,c  

^a HÔPITAL SAINT ANDRÉ   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c Centre of Clinical Investigation Clinical Epidemiology   (France)

Author keywords

Metastatic renal cell carcinoma; Resistance; Sunitinib; Targeted agents; Tyrosine kinase inhibitors

Indexed keywords

BEVACIZUMAB; EVEROLIMUS; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN;

ANGIOGENESIS; BONE MARROW CELL; DOWN REGULATION; DRUG DOSE ESCALATION; FATIGUE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; METASTASIS; NONHUMAN; PROTEINURIA; REVIEW; THERAPY RESISTANCE; UPREGULATION;

ANIMALS; CARCINOMA, RENAL CELL; DRUG RESISTANCE, NEOPLASM; HUMANS; KIDNEY NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 84867143840     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.01.003     Document Type: Review

References (85)

1. Ljungberg B, Cowan N, Hanbury DC, et al. Guidelines on renal cell carcinoma; 2010. Available from: European Association of Urology. http://www.uroweb.org/.
2. Escudier B., Kataja V. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl. 5):v137-v139.
3. Motzer R.J., Hutson T.E., Tomczak P., et al. Overall survival and updated results for sunitinib versus interferon alfa in first-line treatment of patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:3584-3590.
4. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
5. Sternberg C.N., Davis I.D., Mardiak J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28:1061-1068.
6. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-2281.
7. Motzer R.J., Escudier B., Oudard S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456.
8. Escudier B., Bellmunt J., Negrier S., et al. Phase III trial of bevacizumab plus Interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010, 28:2144-2150.
9. Rini B.I., Halabi S., Rosenberg J.E., et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010, 28:2137-2143.
10. Rini B.I., Flaherty K. Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma. Urol Oncol 2008, 26:543-549.
11. Heng DY, Mackenzie MJ, Vaishampayan U, et al. Primary anti-VEGF-refractory metastatic renal cell carcinoma (mRCC): clinical characteristics, risk factors, and subsequent therapy. In: Oral presentation at the American society of clinical oncology genitourinary cancers symposium 2011; 2011 [abstr. 305].
12. Escudier B., Pluzanska A., Koralewski P., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370:2103-2111.
13. Escudier B., Szczylik C., Hutson T.E., et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:1280-1289.
14. Motzer R.J., Escudier B., Oudard S., et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010, 116:4256-4265.
15. Rini B.I., Wilding G., Hudes G., et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009, 27:4462-4468.
16. Cockman M.E., Masson N., Mole D.R., et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000, 275:25733-25741.
17. Kaelin W.G. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 2004, 10:6290S-6295S.
18. Kim W.Y., Kaelin W.G. Role of VHL gene mutation in human cancer. J Clin Oncol 2004, 22:4991-5004.
19. Krause D.S., Van Etten R.A. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005, 353:172-187.
20. Brugarolas J. Renal-cell carcinoma - molecular pathways and therapies. N Engl J Med 2007, 356:185-187.
21. Ciuffreda L., Di S.C., Incani U.C., Milella M. The mTOR pathway: a new target in cancer therapy. Curr Cancer Drug Targets 2010, 10:484-495.
22. Singer E.A., Bratslavsky G., Linehan W.M., Srinivasan R. Targeted therapies for non-clear renal cell carcinoma. Target Oncol 2010, 5:119-129.
23. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008, 8:592-603.
24. Relf M., LeJeune S., Scott P.A., et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997, 57:963.
25. Shojaei F., Wu X., Malik A.K., et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 2007, 25:911-920.
26. Vogelzang N., Hutson T.E., Samlowski W.E., et al. Phase II study of perifosine in metastatic renal cell carcinoma (RCC) progressing after prior therapy (Rx) with a VEGF receptor inhibitor. J Clin Oncol 2009, 27(Suppl.). [abstr. 5034].
27. http://www.clinicaltrials.gov/.
28. Panka D, Kumar M, Schor-Bardach R, et al. Mechanism of acquired resistance to sorafenib in RCC. In: Proceedings of the 99th annual meeting of the American association for cancer research; 2008.
29. Rini B.I., Atkins M.B. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 2009, 10:992-1000.
30. Schor-Bardach R., Alsop D.C., Pedrosa I., et al. Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model?. Radiology 2009, 251:731-742.
31. Casanovas O., Hicklin D.J., Bergers G., Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309.
32. Huang D., Ding Y., Zhou M., et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 2010, 70:1063-1071.
33. Bullock A, Zhang L, O'Neill A, et al. Plasma angiopoietin-2 (ANG2) as an angiogenic biomarker in renal cell carcinoma (RCC). In: Poster presentation at the 46th annual meeting of the American society of clinical oncology, Chicago, Illinois, 4-8 June 2010; 2010.
34. Cuvillier O., Ader I., Bouquerel P., et al. Activation of sphingosine kinase-1 in cancer: implications for therapeutic targeting. Curr Mol Pharmacol 2010, 3:53-65.
35. Bhatt RS, Zhang L, Bullock A, et al. Sphingosine-1-phosphate (S1P) as a novel target in renal cancer (RCC). In: Proceedings of the 101st annual meeting of the American association for cancer research; 2010.
36. Bhatt RS, Zhang L, Schor-Bardach R, et al. Effects of sorafenib administration on the IFN signaling pathway and on the expression of IFN-inducible genes in RCC tumor cells. In: Proceedings of the 99th annual meeting of the American association for cancer research; 2008.
37. Faivre S., Demetri G., Sargent W., Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007, 6:734-745.
38. Ravaud A. Maintenance therapy after CR: CON. In: Oral presentation at the 5th European international kidney cancer, symposium; 2010.
39. Houk B.E., Bello C.L., Poland B., Rosen L.S., Demetri G.D., Motzer R.J. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2010, 66:357-371.
40. Amato R., Harris P.L., Dalton M., Khan M., Alter R., Zhai R. A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). J Clin Oncol 2007, 25(18S Part 1):241s. [abstr. 5026].
41. Amato R.J., Jac J., Harris P., et al. A phase II trial of intra-patient dose escalated-sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). J Clin Oncol 2008, 26. Poster presentation [abstr. 5122].
42. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009, 27:3312-3318.
43. Gore M.E., Jones R., Ravaud A., et al. Efficacy and safety of intrapatient dose escalation of sorafenib as first-line treatment for metastatic renal cell carcinoma. J Clin Oncol 2011, 29(Suppl.). [abstr. 4609].
44. George S., Trent J.C. The role of imatinib plasma level testing in gastrointestinal stromal tumor. Cancer Chemother Pharmacol 2011, 67(Suppl. 1):S45-S50.
45. Faivre S., Delbaldo C., Vera K., et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006, 24:25-35.
46. Khalil B., Hudson J., Williams R., et al. An individualised dose/schedule strategy for sunitinib in metastatic renal cell cancer (mRCC) on progression-free survival (PFS): Correlation with dynamic microbubble ultrasound (DCE-US) data. J Clin Oncol 2011, 29. [abstr. e15149].
47. Hainsworth J.D., Spigel D.R., Burris H.A., Waterhouse D., Clark B.L., Whorf R. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol 2010, 28:2131-2136.
48. Feldman D.R., Baum M.S., Ginsberg M.S., et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:1432-1439.
49. Patel P.H., Senico P.L., Curiel R.E., Motzer R.J. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2009, 7:24-27.
50. Escudier B., Negrier S., Gravis G., et al. Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial. J Clin Oncol 2010, 28. [abstr. 4516].
51. Kabbinavar F., Srinivas S., Hauke R., et al. Results from a phase I trial of tivozanib (AV-951) combined with temsirolimus therapy in patients (pts) with renal cell carcinoma (RCC). J Clin Oncol 2011, 29(Suppl.). [abstr. 4549].
52. Schmidinger M., Bellmunt J. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat Rev 2010, 36:416-424.
53. Medioni J., Banu E., Helley D., et al. Salvage Therapy with Bevacizumab-Sunitinib Combination after Failure of Sunitinib Alone for Metastatic Renal Cell Carcinoma: Case Series. Eur Urol 2009, 56:207-211.
54. Chow L.Q., Eckhardt S.G. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007, 25:884-896.
55. Polverino A., Coxon A., Starnes C., et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 2006, 66:8715-8721.
56. Morabito A., De M.E., Di M.M., Normanno N., Perrone F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 2006, 11:753-764.
57. Morabito A., Piccirillo M.C., Falasconi F., et al. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist 2009, 14:378-390.
58. Sonpavde G., Hutson T.E., Sternberg C.N. Pazopanib for the treatment of renal cell carcinoma and other malignancies. Drugs Today (Barc) 2009, 45:651-661.
59. Albert D.H., Tapang P., Magoc T.J., et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 2006, 5:995-1006.
60. Eskens FA, De Jonge M, Esteves B, et al. Updated results from a phase I study of AV-951 (KRN951), a potent and selective VEGFR-1, -2 and -3 tyrosine kinase inhibitor, in patients with advanced solid tumors. In: Proceedings of the 99th annual meeting of the American association for cancer research; 2008.
61. Hu-Lowe D.D., Zou H.Y., Grazzini M.L., et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 2008, 14:7272-7283.
62. Calvo E., Escudier B., Motzer R.J., et al. Everolimus in metastatic renal cell carcinoma: a subgroup analysis of patients with 1 versus 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase 3 RECORD-1 study. Eur J Cancer 2012, 48:333-339.
63. Porta C., Tortora G., Linassier C., et al. Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement. Med Oncol 2011, 10.1007/s12032-011-0073-z.
64. Rini B.I., Escudier B., Tomczak P., et al. Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of phase III AXIS trial. J Clin Oncol 2011, 29(Suppl.). [abstr. 4503].
65. Sablin M.P., Negrier S., Ravaud A., et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 2009, 182:29-34.
66. Dudek A.Z., Zolnierek J., Dham A., Lindgren B.R., Szczylik C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 2009, 115:61-67.
67. Ambring A., Stierner U., Oden A., Bjorholt I. Sorafenib and sunitinib in renal cell cancer: A study based on register data. J Clin Oncol 2011, 29(Suppl.). [abstr. 4600].
68. Zama I.N., Hutson T.E., Elson P., et al. Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer 2010, 116:5400-5406.
69. Ravaud A., Digue L., Trufflandier N., Smith D. VEGFR TKI 'resistance' or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma. Ann Oncol 2010, 21:431-432.
70. Grunwald V, Seidel C, Fenner M, Heuser M, Ganser A. Antitumor activity of tyrosine kinase inhibitors (TKI) after failure of RAD001 in metastatic renal cell carcinoma (mRCC). In: ASCO 2010 genitourinary cancers symposium; 2010 [abstr. 414].
71. Roca S., Quivy A., Gross-Goupil M., Bernhard J.C., De C.H., Ravaud A. Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors. Acta Oncol 2011, 50:1135-1136.
72. Al-Marrawi M., Rini B.I., Harshman L.C., et al. The association of clinical outcome to front-line VEGF-targeted therapy with clinical outcome to second-lineVEGF-targeted therapy in metastatic renal cell carcinoma (mRCC) patients. J Clin Oncol 2011, 20(Suppl.). [abstr. 4555].
73. Vickers M.M., Choueiri T.K., Rogers M., et al. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology 2010, 76:430-434.
74. Heng D.Y., Mackenzie M.J., Vaishampayan U., et al. Primary ant-VEGF-refractory metastatic renal cell carcinoma (mRCC): Clinical characteristics, risk factors and subsequent therapy. J Clin Oncol 2011, 29(Suppl. 7). [abstr. 305].
75. Mita A.C., Takimoto C.H., Mita M., et al. Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin Cancer Res 2010, 16:3044-3056.
76. Hong DS, Gordon M, Appleman LJ, et al. Interim results from a phase 1B study of safety, pharmacokinetics (PK) and tumor response of the angiopoietin 1/2-neutralizing peptibody AMG 386 in combination with AMG 706, bevacizumab (B) or sorafenib (S) in advanced solid tumors. In: Poster presented at the 33rd European society for medical oncology congress, Stockholm, Sweden, 12-16 September 2008; 2010.
77. Rini BI, Szczylik C, Tannir N, et al. AMG 386 in combination with sorafenib in patients (pts) with metastatic renal cell cancer (mRCC): a randomized, double-blind, placebo-controlled, phase II study. In: American society for clinical oncology 2011 genitourinary cancers symposium; 2011 [abstr. 309].
78. Angevin E, Grunwald V, Lin C, et al. A phase I/II study of TKI258 (dovitinib), a FGFR and VEGFR inhibitor, in patients (pts) with advanced or metastatic renal cell cancer (MRCC): preliminary phase II results. In: Poster presentation at the 35th European society of medical oncology (ESMO), Milan, Italy; 2010.
79. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216.
80. Chen M.Y., Bechtold R.E., Savage P.D. Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GISTs) treated with Gleevec (imatinib mesylate). AJR Am J Roentgenol 2002, 179:1059-1062.
81. Antoch G., Kanja J., Bauer S., et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 2004, 45:357-365.
82. Lassau N., Koscielny S., Albiges L., et al. Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography. Clin Cancer Res 2010, 16:1216-1225.
83. Ravaud A. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist 2011, 16(Suppl. 2):32-44.
84. Roigas J. Clinical management of patients receiving tyrosine kinase inhibitors for advanced renal cell carcinoma. Eur Urol Suppl 2008, 7:593-600.
85. Schmidinger M., Arnold D., Szczylik C., Wagstaff J., Ravaud A. Optimising the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice. Cancer Invest 2010, 28:856-864.